The Long Case For Viking Therapeutics, Inc. (VKTX)

It is interesting to note that Viking Therapeutics, Inc. (NASDAQ:VKTX) is active and made a solid movement in the last trading day. Now trading with a market value of 58.18M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For VKTX, the company currently has 3.39 million of cash on the books, which is offset by 3.05 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 14.32 million in total assets, balanced by 7.73 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Viking Therapeutics, Inc. (VKTX) saw -4.2 million in free cash flow last quarter, representing a quarterly net change in cash of -965,395. Perhaps most importantly where cash movements are concerned, the company saw about -4.2 million in net operating cash flow.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the VKTX saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Viking Therapeutics, Inc. (VKTX) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 24.12 million, this means overall earnings per share of -0.21. Note, this compares with a consensus analyst forecast of -0.19 in earnings per share for its next fiscal quarterly report.

Is Viking Therapeutics, Inc. (NASDAQ:VKTX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.71 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Viking Therapeutics, Inc..

Previous ArticleNext Article

Related Post

Intrexon Corporation (XON) vs. Achaogen, Inc. (AKA... Intrexon Corporation (NYSE:XON) shares are up more than 14.67% this year and recently increased 1.62% or $0.21 to settle at $13.21. Achaogen, Inc. (NA...
A Side-by-side Analysis of Wayfair Inc. (W) and Am... Wayfair Inc. (NYSE:W) shares are up more than 79.29% this year and recently decreased -15.55% or -$11.57 to settle at $62.84. Amazon.com, Inc. (NASDAQ...
Comparing Top Moving Stocks Cabot Oil & Gas C... The shares of Cabot Oil & Gas Corporation have decreased by more than -17.13% this year alone. The shares recently went up by 1.07% or $0.25 and ...
A Side-by-side Analysis of PDL BioPharma, Inc. (PD... PDL BioPharma, Inc. (NASDAQ:PDLI) shares are up more than 37.26% this year and recently decreased -2.02% or -$0.06 to settle at $2.91. Celldex Therape...
Comparing Top Moving Stocks The Kraft Heinz Compan... The shares of The Kraft Heinz Company have decreased by more than -18.03% this year alone. The shares recently went down by -0.41% or -$0.26 and now t...